Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.58−0.07 (-11.13%)
Close on Nov 16, 2026Market cap $8.93MP/E –Yield –
Dare Bioscience operating margin
Operating margin is operating income as a percentage of revenue.
Dare Bioscience's operating margin for the twelve months ending Jun 30, 2026 was -813.4%. For fiscal 2025 it was -1315.5%, against -239692.2% the year before. The highest annual figure on record is -82.3% in fiscal 2016.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1315.5% | +238376.7 |
| FY2024 | Dec 31, 2024 | -239692.2% | −238590.3 |
| FY2023 | Dec 31, 2023 | -1101.9% | −788.0 |
| FY2022 | Dec 31, 2022 | -313.9% | −231.5 |
| FY2016 | Dec 31, 2016 | -82.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1582.5% | +16434.2 |
| Q1 FY2026 | Mar 31, 2026 | -1967.1% | +9261.6 |
| Q4 FY2025 | Dec 31, 2025 | -143.7% | +32655.4 |
| Q3 FY2025 | Sep 30, 2025 | -162340.8% | −97596.9 |
| Q1 FY2025 | Mar 31, 2025 | -18016.7% | −17730.7 |
| Q3 FY2024 | Sep 30, 2024 | -11228.7% | −10389.0 |
| Q2 FY2024 | Jun 30, 2024 | -32799.1% | −32803.0 |
| Q1 FY2024 | Mar 31, 2024 | -64743.9% | −64669.1 |
| Q4 FY2023 | Dec 31, 2023 | -286.1% | −266.9 |
| Q3 FY2023 | Sep 30, 2023 | -839.6% | −815.0 |
| Q2 FY2022 | Jun 30, 2022 | 3.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -74.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -19.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -24.6% | – |
See a number that looks wrong?